What Provention Bio does

Provention Bio was a US-based, clinical- to commercial-stage biopharmaceutical company founded in 2016 and headquartered in Red Bank, New Jersey, that sourced, developed, and commercialized novel therapeutics targeting immune-mediated diseases. The company's stated focus areas included type 1 diabetes, celiac disease, and lupus, with the lead clinical asset being teplizumab, an anti-CD3 monoclonal antibody designed to delay the progression of type 1 diabetes by modulating the immune system's attack on insulin-producing pancreatic beta cells. Teplizumab was granted FDA approval in November 2022 as the first disease-modifying therapy for type 1 diabetes, and subsequently secured approvals in China and the United Kingdom, with a positive EU approval recommendation (branded as Teizeild in the EU). The technology platform was centered on proprietary anti-CD3 antibody biology, supported by issued patents covering methods for preventing or delaying T1D in at-risk non-diabetic subjects, including dosing regimens and immunological markers.

From a business model perspective, Provention Bio generated revenue (where present) primarily through prescription pharmaceutical product sales, with teplizumab (branded Tzield in the US) being the core commercial product following late-2022 FDA approval. The go-to-market motion relied on traditional specialty-pharma channels: physician-targeted detailing, medical science liaison outreach, peer-reviewed publication, and medical conference engagement with endocrinologists and other T1D-treating providers. Distribution post-launch leveraged specialty pharmacies, hospital systems, and retail pharmacy channels. Pre-acquisition, the company operated with 101–250 employees and had raised cumulative equity and debt of approximately $498.5 million across multiple financing rounds between 2017 and early 2023. In March 2023, Provention Bio was acquired by Sanofi for approximately $2.9 billion, after which commercial operations were integrated into Sanofi's global pharmaceutical distribution and sales infrastructure.

Name

Provention Bio

Website

https://proventionbio.com

Company type

Private

Founded year

2016

Operating status

Acquired

Headcount range

101–250 employees

Short description

Provention Bio was a US clinical- to commercial-stage biopharmaceutical company developing disease-modifying therapies for immune-mediated diseases, with teplizumab (Tzield) as the first FDA-approved treatment to delay progression of type 1 diabetes; acquired by Sanofi for $2.9B in March 2023.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

akta.pro secondary industries

Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Type 1 Diabetes Care (HLAKADAB)

Keywords

• Biopharmaceutical therapeutics
• Monoclonal antibody drugs
• Type 1 diabetes therapy
• Immune-mediated disease treatments
• Specialty pharmaceutical products

Headquarters

HQ city

Red Bank

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical product sales: Revenue generated from the sale of prescription pharmaceutical products, primarily teplizumab (branded as Tzield) for type 1 diabetes treatment. As a commercial-stage biopharmaceutical company, Provention Bio was focused on bringing disease-modifying therapies to market through traditional pharmaceutical commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Provention Bio developed and commercialized novel therapeutics for immune-mediated diseases, with its lead product teplizumab (branded as Tzield) being an anti-CD3 monoclonal antibody approved as the first disease-modifying therapy for delaying the progression of stage 3 type 1 diabetes. The company also had pipeline candidates targeting celiac disease and lupus.

Differentiator

Problem solved

Functional benefit

Products and services

• Teplizumab (Tzield/Teizeild)

Quantifiable outcome

• First disease-modifying therapy approved for type 1 diabetes in the US, China, UK, with EU approval recommendation

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Sanofi: Acquired Provention Bio for $2.9 billion in March 2023 to add teplizumab (Tzield) to its immunology portfolio. Comparable because Sanofi is now the direct commercial vehicle for the very asset Provention developed and has deep autoimmune/diabetes infrastructure overlapping with Provention's focus.
• Eli Lilly: Global diabetes incumbent with multiple insulin franchises (Humalog, Humulin, Trulicity, Mounjaro) and active autoimmune R&D. Comparable because Eli Lilly operates in the same diabetes end-market where Provention's Tzield competes for payer budget and physician mindshare.
• Novo Nordisk: World leader in diabetes therapy (insulin, GLP-1, oral semaglutide) with growing autoimmune-adjacent pipeline. Comparable as the dominant incumbent in T1D insulin management — the symptomatic treatment Tzield is designed to delay — making it the most relevant market-context peer.
• Bristol Myers Squibb: Previously developed otelixizumab, a competing anti-CD3 monoclonal antibody for type 1 diabetes. Comparable because BMS pursued the same mechanism of action and clinical indication as Provention's teplizumab, making it the most direct mechanistic precedent in the field.
• Johnson & Johnson: Early equity investor in Provention Bio (2017 round) and broad biopharmaceutical incumbent with diabetes and autoimmune programs. Comparable because J&J represents the type of strategic biopharma investor/acquirer Provention engaged with, and operates in overlapping therapeutic areas.

Direct peers

• MacroGenics: Clinical-stage biopharmaceutical company developing monoclonal antibodies for cancer and autoimmune diseases, including DART and Fc-optimized antibody platforms. Comparable because MacroGenics uses the same modality (mAbs) targeting immune-mediated disease pathways, mirroring Provention's anti-CD3 antibody approach.
• Argenx: Specialty biopharmaceutical focused on antibody therapeutics for severe autoimmune diseases (lead asset efgartigimod/Vyvgart). Comparable because Argenx pursues a similar specialist biotech strategy of advancing differentiated antibody drugs for autoimmune indications, with comparable commercial-stage trajectory.
• Diamyd Medical: Swedish clinical-stage biotech developing Diamyd, a GAD65 antigen-specific immunotherapy for type 1 diabetes. Comparable because Diamyd targets the same disease-modifying mechanism (immune tolerance induction) in T1D, making it the most direct disease-area competitor to Provention's teplizumab.
• Lexicon Pharmaceuticals: Small-cap biopharmaceutical historically focused on diabetes and T1D therapies (e.g., LX4211/sotagliflozin). Comparable because Lexicon pursued disease-modifying approaches to T1D alongside insulin management, operating at a similar company scale and clinical-stage profile.
• Mannkind Corporation: Commercial-stage biopharmaceutical with Afrezza (inhaled insulin) and endocrine disease pipeline (Tyvaso DPI, MNK-6105). Comparable because Mannkind is a small-cap, commercially focused diabetes biopharma with a single lead asset model similar to Provention's teplizumab-centric strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/proventionbio
• LinkedInlinkedin.com/company/provention-bio

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds7 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Provention Bio